HOME > ACADEMIA
ACADEMIA
- Industry-Academia-Government Research Group to Build Adjuvant Database, Support Next-Generation Vaccine Development
March 29, 2012
- Prof. Nakamura Renews Call for Establishment of Drug Discovery Support Organization
March 9, 2012
- Insulin Stockpiles Insufficient at Medical Facilities in Disaster-Hit Areas: JDS Survey
March 6, 2012
- Osaka Medical Center President Hori says “Once-Daily Xarelto is Easy to Take”
February 27, 2012
- JAS 2012 GL Calls for Consideration of Medication for Primary Prevention in Patients with LDL-C Levels Over 180 mg/dL
February 7, 2012
- Demand for Celecox Expected to Increase for Acute Pain Relief: Prof. Ishiguro
January 26, 2012
- Manufacturers Report on Patient Benefits of Oral RI Drugs
January 24, 2012
- JDS to Use NGPS Score for HbA1c in Clinical Practices from April
January 23, 2012
- A New Industry Could Be Created in the Field of Pre-Symptomatic Medical Intervention: Kyoto Univ. Prof. Kawakami
January 16, 2012
- Specialists Debate Pro, Cons of Early Pharm. Intervention in Dementia
January 16, 2012
- MD Studies Could Increase Development Success Rate to 30%: Prof. Sugiyama
December 20, 2011
- Kyushu University Professor Egashira Says Suppression of Vascular Inflammation Can Be Target for Development
November 30, 2011
- JDA Requests Additional Indication of Pustular Psoriasis for Humira
November 22, 2011
- JSMO Issues 33 Development Requests for Unapproved Drugs, Indications
November 22, 2011
- JUA Negative about OTC Switching of Propiverine Hydrochloride
November 17, 2011
- PSJ Preparing for Exchange of Views with JAMS on Switch-OTC Drug Candidates
November 15, 2011
- Teriparatide “Strongly Recommended” for Non-vertebral Fracture: JOS Draft GLs
November 7, 2011
- “No Major Ethnic Differences” in Pharmacokinetics of 3 Drugs Reported
November 1, 2011
- JSGM Calls for Elimination of GE Drug Refusal Option in Prescriptions
October 28, 2011
- JSGM Calls For Elimination of GE Drug Refusal Option in Prescriptions
October 27, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…